KBI Biopharma, Inc. (KBI) and Selexis SA, both JSR Life Sciences companies, appointed

 J.D. Mowery as CEO.

Mowery has nearly a 25-year track record of inspiring colleagues and building organizations. He will lead KBI and Selexis into the next chapter of becoming a leader in the next generation of CDMOs that are emerging.

“Through decades of service, J.D. has devoted his career to meaningful work with a clear focus on patient impact through the launch of novel therapies and by providing world-class service to manufacturing and development partners,” said Tim Lowery, president of JSR Life Sciences. “As we enter a pivotal growth phase, J.D. will play a crucial role in leading KBI and Selexis and empowering our global teams to succeed through servant leadership. We are confident his commitment to our long-term impact will guide us to greater success.”

Mowery will leverage his extensive global biopharmaceutical industry experience in operations, manufacturing, tech transfer, facility construction, business development, employee growth, and investor relations. Previously having worked on both sides of the industry with innovators such as Genentech, Celgene, Juno, and most recently, Treadwell Therapeutics, as well as CDMOs Lonza and AGC Biologics, he acquired expertise across diverse modalities including small molecule, biologics, and cell and gene therapy.

“It is an honor to join KBI and Selexis at the perfect inflection point where we can leverage the collective knowledge, scientific expertise, and resources of the entire JSR ecosystem,” said Mowery. “I’m fortunate to work with an amazingly talented team and energized that our current and future partners will see us positively disrupt the industry as an example of a true next-generation CDMO.”

He added, “I truly look forward to leading KBI and Selexis with a relentless focus on realizing our full potential for our people, partners, and most importantly, the patients across the globe that we serve together.”